Trials / Withdrawn
WithdrawnNCT01736878
Efficacy and Safety Study of Sorafenib to Treat Advanced Medullary Thyroid Carcinoma
Randomized Double-blind Placebo Controlled Phase II Study to Evaluate the Efficacy and Safety of Sorafenib Treatment in Patients With Advanced (Recurrent, Persistent and/or Metastasizing) Medullary Thyroid Carcinoma
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Eanm Research Ltd · Network
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of his study is to evaluate the efficacy and safety of Sorafenib versus placebo in subjects with locally advanced medullary thyroid cancer (MTC). The primary study objective is to compare the Progression-free Survival (PFS) of the Sorafenib treatment group with the placebo treatment group in patients with advanced MTC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sorafenib |
Timeline
- Start date
- 2012-10-01
- Primary completion
- 2013-04-01
- Completion
- 2013-04-01
- First posted
- 2012-11-29
- Last updated
- 2013-05-17
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT01736878. Inclusion in this directory is not an endorsement.